Graves’ Disease

Graves’ disease is an autoimmune disease in which stimulating autoantibodies activate the thyroid-stimulating hormone receptor, causing the thyroid gland to enlarge and produce excessive thyroid hormones. It is a major cause of hyperthyroidism and the most common cause in the United States. Although primarily associated with thyroid overactivity, it can also involve tissues outside the thyroid, particularly those surrounding the eyes. (niddk.nih.gov)

Its effects range from heat intolerance, weight loss, tremor, and palpitations to cardiovascular and skeletal complications. Diagnosis combines thyroid-function testing with evidence identifying the autoimmune cause. Established treatments control hormone synthesis or reduce functioning thyroid tissue, while thyroid eye disease may require separate treatment. The disease’s course, likelihood of remission, and implications for pregnancy and childhood distinguish it from other causes of thyroid hormone excess. (niddk.nih.gov)

Disease identity and nomenclature

Graves’ disease is an autoimmune disease in which the immune response abnormally stimulates the thyroid gland. Its defining mechanism is the production of stimulating autoantibodies against the receptor for thyroid-stimulating hormone (TSH). These antibodies activate thyroid cells, promoting glandular growth and excessive production and secretion of thyroid hormones, principally thyroxine (T4) and triiodothyronine (T3). The term therefore identifies an underlying autoimmune cause, rather than simply an abnormal hormone concentration or a collection of symptoms. Although the thyroid is its principal target, associated autoimmune manifestations may involve tissues outside the gland, particularly those of the eye sockets. (pmc.ncbi.nlm.nih.gov)

Graves’ disease, hyperthyroidism, and thyrotoxicosis describe different levels of this process. Hyperthyroidism means increased synthesis and secretion of thyroid hormone by the thyroid itself; Graves’ disease is one cause, whereas independently functioning thyroid nodules provide another. Thyrotoxicosis is the broader clinical state resulting from excessive thyroid-hormone action, regardless of the hormone’s source. It can therefore arise without hyperthyroidism—for example, when destructive thyroiditis releases previously stored hormone, or when excessive thyroid hormone is supplied from outside the body. Graves’ hyperthyroidism denotes the overactive thyroid state specifically attributable to Graves’ autoimmunity; the terms are not interchangeable with every form of thyroid-hormone excess. (ncbi.nlm.nih.gov)

“Diffuse toxic goiter” is a traditional descriptive name for the typical thyroid presentation. “Diffuse” indicates involvement throughout the gland rather than overactivity confined to one or several nodules; “toxic” refers to the associated thyrotoxicosis, not infection or poisoning; and goiter means thyroid enlargement. This terminology emphasizes the gland’s structure and function, whereas “Graves’ disease” emphasizes a specific disease entity. Enlargement alone is not specific to Graves’ disease: a goiter can accompany normal, increased, or decreased thyroid function. Conversely, some people with Graves’ disease do not develop clinically apparent thyroid enlargement. (en.wikipedia.org)

The eponym commemorates Robert James Graves (1796–1853), an Irish physician whose description of goiter associated with protruding eyes was published in 1835. The German physician Karl Adolph von Basedow (1799–1854) independently described the characteristic constellation in 1840. “Basedow disease,” particularly associated with continental European naming traditions, and “Graves–Basedow disease” refer to the same disorder rather than separate subtypes. “Exophthalmic goiter” is another historical designation, reflecting the prominence of eye protrusion in early descriptions rather than a requirement that every affected person have this feature. (en.wikipedia.org)

Neither eye involvement nor goiter is a universal diagnostic requirement. The American Thyroid Association estimates that approximately one-third of affected people develop symptoms or signs of thyroid eye disease, so its absence does not exclude Graves’ disease. Likewise, a visibly enlarged thyroid is a useful clinical clue but not its defining feature. Modern identification rests on establishing the autoimmune cause of thyroid stimulation, particularly through TSH-receptor antibodies, interpreted alongside thyroid-function measurements and, where appropriate, imaging. Eye disease can occasionally occur with normal or low thyroid-hormone levels, further distinguishing the autoimmune disorder from its usual hyperthyroid presentation. (thyroid.org)

Epidemiology and susceptibility

Graves’ disease is the most common cause of hyperthyroidism in the United States. The National Institute of Diabetes and Digestive and Kidney Diseases estimates that it affects nearly 1 in 100 Americans and accounts for approximately four-fifths of US hyperthyroidism cases. The population proportion affected—prevalence—is distinct from incidence, which measures new cases arising over a specified period. For example, prospective registration in Stockholm during 2003–2005 found an annual incidence of Graves’ disease of 24.5 new cases per 100,000 adults. That regional incidence estimate and the US prevalence estimate describe different populations and different measures of disease frequency; they are not interchangeable. (niddk.nih.gov)

Women are affected substantially more often than men: the American Thyroid Association describes a female-to-male frequency ratio of approximately 7–8 to 1. Graves’ disease usually appears in mid-adulthood but can occur at any age, including childhood and older adulthood. Hormonal factors may contribute to the sex difference, although female predominance does not establish a single hormonal cause. Age and sex therefore describe population-level susceptibility rather than diagnostic requirements: neither male sex nor an age outside the usual adult presentation excludes the disease. (thyroid.org)

Familial clustering reflects a substantial genetic contribution, but inheritance does not follow a simple dominant, recessive, or sex-linked pattern. A family history of Graves’ disease or Hashimoto thyroiditis is associated with increased susceptibility. In a Danish population-based twin study published in 2001, concordance for clinically overt Graves’ disease in the combined cohorts was approximately 35% among identical twins and 3% among non-identical twins. Statistical modelling attributed 79% of variation in underlying disease liability to genetic factors in that study population. This estimate is not a 79% probability that an affected parent will transmit the disease; the incomplete concordance even between identical twins also demonstrates that shared DNA does not determine the outcome by itself. (niddk.nih.gov)

The genetic architecture involves multiple susceptibility variants rather than one disease-causing gene. Associated regions include the human leukocyte antigen complex, whose proteins help the immune system distinguish and respond to antigens. Other associated genes participate in immune regulation or normal thyroid function. Most identified variants individually have small effects on overall risk. This combination of multiple genetic influences and environmental factors explains why the condition can cluster within families without affecting every close relative. (medlineplus.gov)

Cigarette smoking is an established risk association, particularly for Graves’ eye involvement. A 2005 prospective analysis of 115,109 women in the Nurses’ Health Study II found an adjusted hazard ratio for Graves’ hyperthyroidism of 1.93 among current smokers and 1.27 among former smokers compared with never-smokers. Smoking is also associated with more severe eye abnormalities in affected people. These observations identify increased risk, not a necessary exposure or a demonstrable individual cause. Graves’ disease also co-occurs with other autoimmune diseases, including type 1 diabetes and rheumatoid arthritis, as well as vitiligo and autoimmune gastritis. Such clustering is consistent with overlapping autoimmune susceptibility; it does not establish that one of these disorders directly causes another. (pubmed.ncbi.nlm.nih.gov)

Autoimmune mechanisms and thyroid physiology

Normal thyroid activity is regulated by thyroid-stimulating hormone (TSH), released by the anterior pituitary gland. TSH binds to the TSH receptor on thyroid follicular cells and stimulates the synthesis and secretion of thyroxine (T4) and triiodothyronine (T3). The thyroid secretes predominantly T4; much of the body’s T3 is produced by conversion of T4 in other tissues. Circulating thyroid hormones participate in a negative-feedback system: when their availability increases, pituitary TSH secretion decreases; when availability falls, TSH secretion increases. This regulation normally matches thyroid output to physiological requirements rather than allowing continuous maximal stimulation. (thyroid.org)

In Graves’ disease, loss of immune tolerance permits an immune response against the body’s own TSH receptor. Thyroid-antigen-reactive T cells infiltrate the gland, while autoreactive B cells give rise to antibody-secreting cells. Helper T-cell signals support B-cell activation and the production of receptor-directed autoantibodies. The resulting response is not simply nonspecific thyroid inflammation: its characteristic functional product is an antibody capable of activating a normal hormone receptor. Direct experimental evidence includes the identification of TSH-receptor-specific T cells from affected thyroid tissue and B cells capable of producing receptor antibodies from patients’ blood. (pmc.ncbi.nlm.nih.gov)

Stimulating TSH-receptor antibodies, also termed thyroid-stimulating antibodies (TSAb) or thyroid-stimulating immunoglobulins (TSI), mimic the receptor-activating action of TSH. The receptor is coupled to intracellular signaling pathways, notably the cyclic adenosine monophosphate (cAMP) pathway, which promotes thyroid-cell function and growth. Antibody-driven activation therefore increases hormone synthesis and secretion while also promoting follicular-cell hyperplasia, the increase in cell number underlying diffuse thyroid enlargement. Unlike transient release of stored hormones from damaged tissue, this mechanism continuously stimulates the gland’s hormone-producing machinery. The 2018 European Thyroid Association guideline identifies receptor stimulation as the link between the autoimmune response, thyroid hyperplasia, and unregulated hormone production. (pmc.ncbi.nlm.nih.gov)

The apparent paradox of excessive thyroid activity despite very low TSH follows from the separation of pituitary regulation and antibody production. Rising T4 and T3 appropriately suppress pituitary TSH, but this feedback does not directly switch off the autoreactive cells producing stimulating antibodies. Consequently, the gland remains activated even when its normal pituitary stimulus is nearly absent. Low TSH in this setting reflects the pituitary’s response to hormone excess, not the signal causing hyperthyroidism. The autoimmune stimulus effectively bypasses the normal regulatory relationship between circulating thyroid hormones and thyroid output. (thyroid.org)

“TSH-receptor antibodies” is a broader category than stimulating antibodies. Some receptor-directed antibodies block TSH action instead; stimulating and blocking activities can coexist, and their relative effects influence thyroid function. Antibodies against thyroid peroxidase, an enzyme involved in hormone synthesis, or thyroglobulin, the protein scaffold used to make thyroid hormones, recognize different targets. They may accompany Graves’ disease but do not establish that the TSH receptor is being stimulated. Thus, evidence of thyroid autoimmunity is biologically distinct from evidence of the particular receptor-activating mechanism responsible for Graves’ hyperthyroidism. (thyroid.org)

Thyroid and systemic clinical manifestations

The thyroid is often diffusely and symmetrically enlarged, producing a goiter rather than a single dominant lump. Enlargement varies from a gland detectable only on physical examination to visible swelling across the lower front of the neck. Increased thyroid blood flow may produce an audible bruit—a vascular sound heard with a stethoscope. Some patients notice neck fullness, tightness, or pressure; larger goiters can interfere with swallowing or breathing by compressing adjacent structures. Marked enlargement is not universal, and a palpable goiter is less common in older patients. These local effects reflect gland enlargement rather than the systemic effects of excess thyroid hormone. (thyroid.org)

Metabolic and temperature-related manifestations include weight loss despite a normal or increased appetite, excessive sweating, and difficulty tolerating heat. Increased metabolic activity raises energy expenditure and heat production, so patients may feel unusually warm in conditions comfortable to others. The skin may be warm and moist. Weight loss is characteristic but not obligatory: increased food intake can offset the greater energy expenditure, and some patients maintain or gain weight. Symptoms commonly develop gradually over weeks or months rather than appearing simultaneously. (niddk.nih.gov)

Cardiovascular manifestations include palpitations, a rapid resting pulse, and a forceful or pounding heartbeat. Thyroid hormone excess increases heart rate, the volume pumped with each beat, and overall cardiac output; systolic blood pressure may also rise. Neuromuscular findings include a fine hand tremor, brisk reflexes, reduced exercise tolerance, and muscle weakness. Weakness particularly affects proximal muscles around the shoulders and hips, making activities such as climbing stairs or rising from a chair more difficult. In older adults, weight loss, fatigue, or cardiovascular symptoms may dominate, while tremor and conspicuous hyperactivity are less evident. (ncbi.nlm.nih.gov)

Gastrointestinal manifestations commonly take the form of more frequent bowel movements; diarrhea can occur but is not required. Menstrual bleeding may become lighter, cycles may become less frequent or irregular, and menstruation may cease. These changes accompany the systemic effects of hyperthyroidism and are not specific to Graves’ disease. Their presence alongside heat intolerance, tremor, or palpitations provides a recognizable multisystem pattern, although individual patients need not exhibit every feature. (niddk.nih.gov)

Nervousness, irritability, restlessness, difficulty concentrating, and sleep disturbance may accompany pronounced fatigue. Increased physiological activation therefore does not necessarily translate into greater stamina: patients may feel both restless and exhausted. Anxiety-like symptoms can include a sense of tension together with shaking, sweating, and awareness of the heartbeat. These are recognized manifestations of thyroid hormone excess and do not, by themselves, establish an independent psychiatric diagnosis. Conversely, a less activated presentation can occur in older adults, with apathy or withdrawal rather than obvious agitation. (thyroid.org)

Eye, skin, and other extrathyroidal manifestations

Thyroid eye disease (TED), also called Graves’ orbitopathy or ophthalmopathy, is an autoimmune disorder of the tissues within the orbit rather than simply an effect of excess circulating thyroid hormone. Orbital fibroblast activation, immune-cell recruitment, and inflammation promote accumulation of water-binding glycosaminoglycans, expansion of orbital fat, and enlargement of extraocular muscles; subsequent fibrosis contributes to persistent tissue remodeling. Upper-eyelid retraction alone is not specific for this process: it can accompany thyrotoxicosis of any cause and does not, by itself, establish autoimmune orbital disease. (eyewiki.aao.org)

Characteristic manifestations include eyelid retraction, forward displacement of the globe (proptosis or exophthalmos), swollen eyelids, conjunctival redness, grittiness, light sensitivity, tearing, and orbital discomfort. Incomplete eyelid closure exposes the ocular surface and contributes to dryness and irritation. Enlarged or fibrotic extraocular muscles restrict movement and misalign the eyes, producing binocular double vision; inferior rectus involvement commonly restricts upward gaze. Involvement can be bilateral but markedly asymmetric, or clinically unilateral. The American Thyroid Association estimates that about one-third of people with Graves’ disease develop eye symptoms, although estimates vary with the definition and method of assessment. (eyewiki.aao.org)

Inflammatory activity and clinical severity describe different dimensions. Activity concerns ongoing inflammation, particularly pain, redness, and swelling; severity concerns structural changes, functional impairment, and threatened vision. The 2022 American Thyroid Association–European Thyroid Association consensus statement describes a seven-item Clinical Activity Score, with one point for each specified inflammatory finding; a score of at least 3/7 usually indicates active disease. Severity is categorized separately as mild, moderate-to-severe, or sight-threatening. Consequently, persistent proptosis or restrictive double vision can remain important even after inflammation has subsided. Sight-threatening manifestations include corneal breakdown from exposure and dysthyroid optic neuropathy, usually caused by enlarged muscles crowding the orbital apex and compressing the optic nerve. Optic-nerve dysfunction may reduce visual acuity, color perception, or visual fields. (doi.org)

Eye involvement does not necessarily parallel thyroid hormone concentrations. It may precede recognized hyperthyroidism, appear around its onset, or persist after biochemical control; a minority of affected people have normal thyroid function or hypothyroidism. Normalization of hormone levels therefore does not demonstrate resolution of orbital disease, and the severity of hyperthyroidism is not a reliable measure of eye involvement. (thyroid.org)

Pretibial myxedema, also termed thyroid dermopathy, produces localized skin thickening, usually over the shins and sometimes the feet. Dermal glycosaminoglycan accumulation retains water and contributes to nonpitting edema, plaques, or nodules; extensive disease can cause elephantiasis-like enlargement. Despite its name, this localized autoimmune manifestation is distinct from the generalized myxedematous changes of hypothyroidism. A 2002 Mayo Clinic study by Kara M. Schwartz and colleagues followed 178 patients with thyroid dermopathy: 99.4% had pretibial involvement, 43.3% had a predominantly nonpitting-edema pattern, and 97.0% also had ophthalmopathy. These figures describe a selected dermopathy cohort, not prevalence among all patients with Graves’ disease. (pubmed.ncbi.nlm.nih.gov)

Thyroid acropachy is a rare manifestation characterized by digital clubbing, swelling of fingers or toes, and periosteal new-bone formation in the extremities. It is almost always associated with thyroid dermopathy and ophthalmopathy rather than occurring alone. In a separate 2002 Mayo Clinic report, Vahab Fatourechi and colleagues described 40 affected patients identified over 26 years; four of the eight patients who underwent extremity radiography had a periosteal reaction. Clubbing was often detected on examination rather than reported as a symptom. (pubmed.ncbi.nlm.nih.gov)

Diagnosis and differential diagnosis

Biochemical testing establishes thyroid hormone excess but does not, by itself, establish its cause. Overt Graves’ hyperthyroidism typically produces suppressed serum thyroid-stimulating hormone (TSH) with elevated free thyroxine (T4) and/or triiodothyronine (T3). In T3-predominant disease, T3 is elevated while free T4 remains within its reference range; measuring T4 alone can therefore miss this presentation. Subclinical hyperthyroidism denotes low TSH with normal free T4 and T3, rather than necessarily an absence of symptoms. These biochemical patterns require etiological interpretation: the same suppressed TSH can accompany Graves’ disease, autonomous thyroid nodules, or hormone release from an inflamed gland. (pmc.ncbi.nlm.nih.gov)

Testing for TSH-receptor autoantibodies (TRAb) helps identify the autoimmune cause. Competitive-binding assays, often termed TSH-binding inhibitory immunoglobulin assays, detect antibodies that bind the receptor but do not determine whether they stimulate or block it. Functional cell-based bioassays instead measure receptor activation, for example through cyclic AMP-dependent reporter activity, and distinguish stimulating from blocking antibodies. The 2018 European Thyroid Association guideline reported pooled sensitivity of 97% and specificity of 98% for second- and third-generation binding assays in a meta-analysis of 21 studies. Thus, positive TRAb strongly supports Graves’ disease in a compatible biochemical setting, although a negative result does not exclude every case. (pmc.ncbi.nlm.nih.gov)

Thyroid scintigraphy and radioactive iodine uptake testing assess related but distinct features: uptake quantifies tracer accumulation, while scintigraphy maps its distribution. Graves’ disease usually produces increased uptake distributed diffusely throughout the gland, reflecting widespread stimulation of functioning thyroid tissue. By contrast, a toxic adenoma produces a focal “hot” region with suppression of the surrounding thyroid, whereas toxic multinodular goiter produces an uneven distribution across several functioning nodules. Recent iodine exposure, including iodinated radiographic contrast, can lower uptake and complicate interpretation; an unexpectedly low result is therefore not automatically evidence against increased hormone synthesis. (niddk.nih.gov)

Doppler ultrasonography detects the increased thyroid blood flow associated with Graves’ disease without administering a radioactive tracer. It can provide supporting evidence when uptake testing is unsuitable, including during pregnancy or breastfeeding. A conventional ultrasound examination also characterizes gland size and nodules, but structural appearances alone do not establish the autoimmune cause. When biochemical findings and receptor-antibody results are convincing, radionuclide imaging is not invariably necessary; imaging is particularly informative when the cause remains uncertain or nodular autonomy is suspected. (niddk.nih.gov)

The principal low-uptake alternatives involve circulating hormone that is not being newly synthesized by the thyroid. In destructive thyroiditis, damaged follicles release stored hormone, producing thyrotoxicosis despite near-absent radioactive iodine uptake. Externally supplied thyroid hormone, including excessive levothyroxine, likewise suppresses TSH and thyroid uptake. Serum thyroglobulin can help distinguish these mechanisms: it is released with hormone during destructive thyroiditis but is usually suppressed during exogenous hormone administration. Anti-thyroglobulin antibodies can interfere with the measurement, limiting its interpretation. Medication and supplement exposure, receptor antibodies, uptake distribution, and blood-flow findings therefore distinguish conditions with similar initial thyroid-function results. (doi.org)

Complications of hormone excess

Sustained thyroid hormone excess increases heart rate, cardiac contractility, and cardiac output while reducing systemic vascular resistance. These changes increase cardiac workload and can contribute to exercise intolerance and impaired cardiac function. Atrial fibrillation is an important complication rather than simply another form of palpitations: disorganized atrial electrical activity produces an irregular rhythm and can promote clot formation and embolic stroke. In a Danish registry study published in 2004, Lars Frost and colleagues found atrial fibrillation or flutter in 3,362 of 40,628 patients with hospital-diagnosed hyperthyroidism—8.3%—within 30 days before or after diagnosis. This figure included different causes of hyperthyroidism and is not a Graves-specific prevalence estimate; increasing age and pre-existing cardiac disease were associated with greater risk. (pmc.ncbi.nlm.nih.gov)

Heart failure can develop when the increased circulatory demand exceeds cardiac reserve, especially in older people or those with underlying cardiovascular disease. Persistent rapid rhythms can further impair ventricular performance. Thus, an initially hyperdynamic circulation does not exclude subsequent cardiac decompensation: clinically significant failure may produce breathlessness, pulmonary congestion, and peripheral edema. Atrial fibrillation also need not disappear when thyroid function normalizes. In a retrospective hospital cohort published in 2017, approximately one-third of patients with thyrotoxic atrial fibrillation had persistent arrhythmia, distinguishing an established cardiovascular complication from transient awareness of a rapid heartbeat. (niddk.nih.gov)

Excess thyroid hormone accelerates bone remodeling, increasing both bone resorption and formation but shifting the balance toward net loss. Human bone-biopsy studies have demonstrated increased osteoclast-mediated resorption, greater cortical porosity, and reduced trabecular bone. Sustained exposure can therefore reduce bone mineral density and contribute to osteoporosis and fractures; these are structural complications, unlike nonspecific aches or fatigue. Bone loss is not confined to postmenopausal women. A prospective study published in 2010 followed 32 premenopausal women with newly diagnosed Graves’ disease and found lower bone mineral density during untreated thyrotoxicosis than in controls, with significant improvement during approximately 18 months of antithyroid treatment. (pubmed.ncbi.nlm.nih.gov)

Muscular involvement likewise extends beyond the subjective weakness that may accompany initial presentation. Established thyrotoxic muscle dysfunction can involve objectively reduced strength, endurance, and muscle mass. A 1991 prospective study of ten newly diagnosed Graves’ patients documented substantial impairment in proximal and distal muscle performance, with further recovery to control levels after euthyroidism was established approximately six months later. Another physiological study found that recovery reflected both increased muscle mass and improved intrinsic contractile function, rather than weight gain alone. (pubmed.ncbi.nlm.nih.gov)

Thyroid storm is a rare, life-threatening decompensation of thyrotoxicosis involving multiple organ systems, often precipitated by infection, interruption of antithyroid medication, or major physiological stress. Features include fever, marked tachycardia or arrhythmia, heart failure, vomiting or diarrhea, hepatic dysfunction or jaundice, and altered mental status ranging from delirium to coma. It is distinguished from uncomplicated hyperthyroidism by systemic decompensation, not by a particular thyroid hormone concentration: a Japanese nationwide study published in 2012 found overlapping free thyroid hormone levels in storm and non-storm thyrotoxicosis. Among 356 definite or suspected cases identified for 2004–2008, mortality was approximately 10.7%; multiple-organ failure and congestive heart failure were leading causes of death. Thyroid storm is consequently classified as a medical emergency requiring hospital-based care. (pmc.ncbi.nlm.nih.gov)

Established treatments and their mechanisms

Methimazole, carbimazole, and propylthiouracil are thionamide drugs that reduce thyroid-hormone synthesis. They inhibit thyroid peroxidase, interfering with iodide oxidation, incorporation of iodine into thyroglobulin, and coupling reactions that produce thyroxine (T4) and triiodothyronine (T3). Carbimazole is a prodrug converted to methimazole; propylthiouracil additionally inhibits peripheral conversion of T4 to T3. These drugs do not immediately remove stored or circulating hormone, so biochemical improvement takes weeks rather than hours. Methimazole is the usual antithyroid drug outside specific circumstances such as early pregnancy. Treatment can preserve functioning thyroid tissue, unlike ablation or total gland removal. (pmc.ncbi.nlm.nih.gov)

Important drug risks include rash, agranulocytosis, and liver injury. The 2018 European Thyroid Association guideline reported agranulocytosis—profound depletion of infection-fighting neutrophils—in approximately 0.1–1.0% of treated patients, usually with abrupt onset during the first three months. Propylthiouracil can cause severe hepatocellular injury, including liver failure; methimazole and carbimazole more characteristically cause cholestatic injury. Beta blockers, including propranolol and atenolol, serve a different purpose: blocking adrenergic effects reduces tachycardia, tremor, and palpitations without directly suppressing thyroid-hormone synthesis. Their symptomatic effects can begin within hours, before antithyroid drugs have substantially reduced hormone concentrations. (pmc.ncbi.nlm.nih.gov)

Radioiodine treatment administers iodine-131 orally as a capsule or liquid. Thyroid follicular cells concentrate the isotope through the same uptake process used for ordinary iodine; its radioactive decay delivers beta radiation that damages hormone-producing tissue. Destruction develops gradually, and some patients require repeat treatment. Permanent hypothyroidism is a common intended outcome of ablative treatment and is managed with levothyroxine replacement. Radioiodine can precipitate or worsen thyroid eye disease, an effect that distinguishes it from simply lowering circulating hormone levels. It is excluded during pregnancy and breastfeeding. (niddk.nih.gov)

Thyroidectomy instead removes hormone-producing tissue physically. Total thyroidectomy offers rapid, definitive elimination of thyroid overproduction and has a lower recurrence risk than subtotal removal, but necessarily produces permanent hypothyroidism requiring lifelong replacement. Major operative complications include recurrent laryngeal nerve injury, which can impair vocal-cord movement and voice; damage to or loss of parathyroid function, causing hypocalcemia; and postoperative hemorrhage. Wound infection and anesthesia-related complications are additional risks. Preoperative control of hyperthyroidism reduces the risk of perioperative thyrotoxic deterioration; short-term iodide preparations can reduce thyroid vascularity and operative blood loss. Complication rates depend partly on surgical experience and case volume. (pmc.ncbi.nlm.nih.gov)

Thyroid eye disease requires separate treatment because orbital inflammation and tissue remodeling may persist despite normalized thyroid function. Ocular lubricants address surface irritation, whereas systemic corticosteroids, particularly intravenous methylprednisolone, suppress active orbital inflammation. Targeted biological treatment includes teprotumumab, a monoclonal antibody against the insulin-like growth factor-1 receptor that interrupts signaling implicated in orbital tissue expansion. In the 2020 phase 3 OPTIC trial led by Raymond S. Douglas and colleagues, a reduction in proptosis of at least 2 mm at week 24 occurred in 83% of teprotumumab recipients versus 10% receiving placebo. Important adverse effects include hyperglycemia and hearing impairment. (niddk.nih.gov)

Orbital decompression creates additional space by removing selected orbital bone, fat, or both, reducing protrusion and pressure on the optic nerve. Sight-threatening optic neuropathy can require urgent corticosteroid treatment and decompression rather than waiting for disease inactivity. Elective rehabilitation generally follows a different timetable: after orbital disease becomes inactive and thyroid function is stable, procedures are staged as decompression first, eye-muscle surgery for persistent double vision second, and eyelid correction last. This sequence accounts for the effects that each operation can have on subsequent eye alignment and eyelid position. (journals.sagepub.com)

Pregnancy, postpartum disease, and neonatal effects

Pregnancy changes both thyroid physiology and the interpretation of thyroid-function tests. Human chorionic gonadotropin (hCG) weakly stimulates the TSH receptor, increasing thyroid hormone production and lowering pituitary TSH, particularly near the end of the first trimester. Estrogen increases thyroxine-binding globulin, raising total T4 and T3 concentrations without necessarily indicating hyperthyroidism. Laboratory interpretation therefore uses pregnancy- and assay-appropriate reference ranges rather than nonpregnant thresholds alone. Gestational transient thyrotoxicosis is an hCG-mediated, nonautoimmune condition, often associated with severe pregnancy-related vomiting. Unlike Graves’ disease, it generally lacks TSH-receptor antibodies, thyroid eye disease, and a preceding history of thyrotoxicosis. This distinction matters because gestational transient thyrotoxicosis usually resolves as pregnancy progresses and generally does not require antithyroid medication. (journals.sagepub.com)

Maternal and fetal thyroid status can differ because TSH-receptor autoantibodies cross the placenta and stimulate the fetal thyroid independently of maternal thyroid hormone concentrations. Fetal or neonatal hyperthyroidism occurs in approximately 1–5% of pregnancies affected by maternal Graves’ disease, principally when stimulating-antibody concentrations are high. Previous thyroidectomy or radioactive iodine ablation does not eliminate this possibility: circulating antibodies can persist even when the mother has hypothyroidism controlled with levothyroxine. Consequently, maternal biochemical control alone does not establish that the fetus is unaffected. Antibody measurement early in pregnancy, with repeat testing around 18–22 weeks when initially elevated, helps identify pregnancies requiring additional fetal assessment. (thyroid.org)

Persistent maternal antibody concentrations exceeding three times the assay’s upper reference limit identify increased fetal risk. Assessment can include ultrasonography for fetal goiter, growth disturbance, and signs of thyroid-related cardiovascular dysfunction. The 2016 American Thyroid Association guideline also specified repeat antibody testing at 30–34 weeks when concentrations remained elevated at 18–22 weeks, helping determine the need for neonatal monitoring. Maternal antithyroid medicines cross the placenta as well: they can restrain antibody-driven fetal hormone production, but excessive exposure can instead produce fetal hypothyroidism and goiter. Thus, antibodies and medicines can exert opposing effects on the fetal thyroid. (doi.org)

Medication choice reflects competing maternal and developmental risks. Methimazole, including exposure through its prodrug carbimazole, is associated with a characteristic embryopathy that can include scalp skin defects and choanal or esophageal atresia, especially during gestational weeks 6–10. Propylthiouracil is generally preferred during the first trimester because its associated birth defects tend to be less severe, although it is not risk-free. Its potential for serious maternal liver injury favors consideration of methimazole later in pregnancy; the 2018 European Thyroid Association guideline specified consideration of a switch after 16 weeks. Treatment uses the lowest effective antithyroid exposure, with maternal free T4 maintained near the upper pregnancy-specific reference limit rather than attempting to normalize TSH through increasingly intensive blockade. Radioactive iodine treatment is contraindicated during both pregnancy and breastfeeding. (pmc.ncbi.nlm.nih.gov)

Graves’ activity often diminishes during the second and third trimesters as pregnancy-associated immune changes reduce stimulating-antibody production, but it may worsen again after delivery. Postpartum thyrotoxicosis therefore requires distinction between recurrent or newly apparent Graves’ disease and postpartum thyroiditis. The latter releases previously stored hormone through thyroid inflammation rather than sustained receptor-driven synthesis; it may subsequently enter a hypothyroid phase, and antithyroid medicines do not address its mechanism. Breastfeeding itself does not exclude antithyroid medication: only small quantities enter milk, and appropriately limited methimazole or propylthiouracil exposure is compatible with lactation. This differs fundamentally from radioactive iodine therapy, which remains excluded during breastfeeding. (niddk.nih.gov)

Childhood and adolescence

Graves’ disease is uncommon in childhood, although it is the principal cause of pediatric hyperthyroidism. The 2022 European Thyroid Association (ETA) guideline reports annual incidence estimates of approximately 1–2.9 cases per 100,000 children younger than 15 years. Disease frequency increases toward adolescence, with girls affected more often than boys. Pediatric presentation may be dominated by restlessness, reduced attention, disturbed sleep, or declining school performance rather than conspicuous weight loss. These changes can precede recognition of thyroid enlargement, tremor, or persistent tachycardia. (pmc.ncbi.nlm.nih.gov)

Growth and pubertal development provide additional diagnostic clues. Thyroid hormone excess can accelerate linear growth and skeletal maturation; plotting serial height and weight measurements may reveal an increased growth velocity or failure to gain the weight normally expected during puberty. Menstrual irregularities can occur in adolescents. In the hospital-based Japanese series of 132 children cited in Japan’s 2016 pediatric guideline, restlessness occurred in 47.4%, whereas weight loss occurred in 36.1%. Thus, absence of weight loss does not exclude the disease, particularly during a developmental period normally characterized by weight gain. (pmc.ncbi.nlm.nih.gov)

Pediatric diagnosis combines clinical findings with suppressed thyroid-stimulating hormone (TSH), elevated free thyroxine and/or free triiodothyronine, and TSH-receptor autoantibodies. Interpretation requires age- and assay-appropriate laboratory reference intervals: normal thyroid hormone concentrations change through childhood and pubertal development, making uncritical application of adult limits inappropriate. (pmc.ncbi.nlm.nih.gov) The ETA guideline includes receptor-antibody measurement in the investigation of all children with hyperthyroidism. Doppler ultrasonography provides a radiation-free assessment when imaging is needed, while scintigraphy is reserved for particular diagnostic uncertainties. (pmc.ncbi.nlm.nih.gov)

Drug treatment generally extends longer than the conventional 12–18-month adult course. The 2022 ETA guideline specifies methimazole or carbimazole for at least three years, with courses of five years or longer in children with a low likelihood of remission; remission after two years occurs in approximately 20–30%. Dose titration is preferred to routinely blocking thyroid synthesis completely and adding replacement hormone. (pmc.ncbi.nlm.nih.gov) Propylthiouracil differs importantly because of its pediatric liver-safety profile. A 2010 adverse-event analysis by Scott Rivkees and Ana Szarfman found disproportionate reporting of severe liver injury with propylthiouracil in patients younger than 17 years. U.S. prescribing information consequently does not recommend pediatric use except when methimazole is not tolerated and surgery or radioactive iodine is unsuitable. Injury may progress rapidly to liver failure, transplantation, or death, and routine biochemical monitoring does not reliably prevent this outcome. (pubmed.ncbi.nlm.nih.gov)

Definitive treatment requires age-specific consideration. The 2022 ETA guideline excludes radioactive iodine below age five and restricts its use at ages five to ten to circumstances in which surgery is not realistic. Total thyroidectomy is favored for large goiters. (pmc.ncbi.nlm.nih.gov) When definitive treatment is selected, access to an experienced thyroid surgeon, gland size, prior drug reactions, family preferences, and the child’s educational circumstances affect the choice and timing. Both complete thyroidectomy and successful radioiodine ablation produce permanent hypothyroidism, requiring levothyroxine replacement. Transition toward independent medication-taking during adolescence adds a practical dimension: prolonged treatment depends not only on biochemical response but also on sustained adherence and continuity of care into adulthood. (academic.oup.com)

Disease course, remission, and long-term outcomes

Biochemical control means that treatment has restored thyroid hormone concentrations to the reference range; it does not establish that Graves’ disease will remain inactive without treatment. A patient whose hyperthyroidism is controlled by methimazole may still have circulating TSH-receptor antibodies (TRAb). The 2016 American Thyroid Association guideline defines remission as normal serum TSH, free T4, and total T3 maintained for at least one year after antithyroid-drug withdrawal. Relapse is the return of hyperthyroidism after withdrawal. Eliminating thyroid overactivity by radioiodine or thyroidectomy is distinct from immunological remission: receptor-directed autoimmunity can persist after thyroid tissue has been destroyed or removed. (doi.org)

Remission estimates depend on treatment duration, population, and length of follow-up. The 2018 European Thyroid Association guideline reported remission rates of approximately 50–55% following conventional 12–18-month antithyroid-drug courses. Recurrence is most frequent during the first 6–12 months after withdrawal, although it can occur years later. Persistently elevated TRAb at treatment cessation, a larger goiter, and more severe initial hormone excess are associated with recurrence. These are probabilistic markers rather than certain predictions: low or undetectable antibodies improve the likelihood of remission but do not exclude subsequent relapse. (pmc.ncbi.nlm.nih.gov)

Long-term trajectories include sustained drug-free thyroid function, recurrent disease, later ablative treatment, and spontaneous hypothyroidism. A Norwegian follow-up published online in 2023 and in a 2024 journal issue, led by Ann-Elin Meling Stokland, reassessed 182 of 218 participants from an antithyroid-drug trial conducted in 1997–2001. Approximately 25 years after treatment initiation, 34% had normal thyroid function without replacement or antithyroid medication, 13% had spontaneous hypothyroidism, and 1% had active disease; 40% had received radioiodine and 13% thyroidectomy. These rounded proportions describe the experience of this particular cohort, not universal lifetime probabilities. (academic.oup.com)

Thyroid-function surveillance therefore extends beyond initial biochemical recovery. The 2016 American Thyroid Association guideline specifies closer testing during the first year after drug withdrawal and at least annual assessment once remission is established, because both late relapse and hypothyroidism remain possible. Treatment-associated hypothyroidism is an expected consequence of total thyroidectomy and an intended outcome of ablative radioiodine treatment, rather than evidence that the autoimmune disease has changed into remission. Permanent hormone deficiency requires levothyroxine replacement and continuing biochemical assessment of replacement adequacy. (doi.org)

The course of thyroid eye disease is not a direct measure of thyroid hormone control. Its severity does not correlate closely with the severity of hyperthyroidism, and eye disease can occur in people with normal thyroid function or, less commonly, hypothyroidism. Consequently, correction of hormone excess does not by itself establish resolution of orbital disease; thyroid and eye outcomes are assessed separately. (thyroid.org)

Long-term quality of life can remain impaired even after treatment. In a 2005 study, Mirna Abraham-Nordling and colleagues evaluated a cohort of 179 patients originally randomized to antithyroid drugs, radioiodine, or surgery, using questionnaires 14–21 years later. All treatment groups had lower vitality scores than a Swedish reference population, while no major statistically significant quality-of-life differences were detected between treatment modalities. The Norwegian 25-year follow-up likewise documented persistent quality-of-life impairment, particularly among participants who had developed hypothyroidism. These findings distinguish biochemical treatment success from complete patient-reported recovery. (pubmed.ncbi.nlm.nih.gov)

References

1. 2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidismpmc.ncbi.nlm.nih.gov
2. Graves’ Disease and the Manifestations of Thyrotoxicosisncbi.nlm.nih.gov
3. Hyperthyroidism (Overactive Thyroid)niddk.nih.gov
4. Graves' diseaseen.wikipedia.org
5. Goiterthyroid.org
6. Graves' disease: MedlinePlus Geneticsmedlineplus.gov
7. Karl Adolph von Basedowen.wikipedia.org
8. Graves’ Diseasethyroid.org
9. Graves’ Disease — NIDDKniddk.nih.gov
10. Incidence of hyperthyroidism in Stockholm, Sweden, 2003–2005pubmed.ncbi.nlm.nih.gov
11. Graves’ Disease — American Thyroid Associationthyroid.org
12. Evidence for a major role of heredity in Graves’ disease: a population-based study of two Danish twin cohortspubmed.ncbi.nlm.nih.gov
13. Smoking and other lifestyle factors and the risk of Graves’ hyperthyroidismpubmed.ncbi.nlm.nih.gov
14. Thyroid Function Teststhyroid.org
15. Thyroid Testsniddk.nih.gov
16. Identification of Thyroid Stimulating Hormone Receptor–specific T Cells in Graves’ Disease Thyroid Using Autoantigen-transfected Epstein-Barr Virus–transformed B Cell Linesjci.org
17. High frequency of B cells capable of producing anti-thyrotropin receptor antibodies in patients with Graves' disease.pubmed.ncbi.nlm.nih.gov
18. Hyperthyroidism | American Thyroid Associationthyroid.org
19. Thyroid Function Tests | American Thyroid Associationthyroid.org
20. ATA Patient Informationthyroid.org
21. Graves Disease - StatPearls - NCBI Bookshelfncbi.nlm.nih.gov
22. Goiter - ENT Healthenthealth.org
23. Clinical Thyroidology for Patients August 2011thyroid.org
24. Hyperthyroidism | Graves' Disease | Overactive Thyroid | MedlinePlusmedlineplus.gov
25. Thyroid Eye Disease — EyeWikieyewiki.aao.org
26. Thyroid Eye Disease — American Thyroid Associationthyroid.org
27. Pretibial myxedema: pathophysiology and treatment optionspubmed.ncbi.nlm.nih.gov
28. Dermopathy of Graves' disease (pretibial myxedema): long-term outcomepubmed.ncbi.nlm.nih.gov
29. Thyroid acropachy: report of 40 patients treated at a single institution in a 26-year periodpubmed.ncbi.nlm.nih.gov
30. Graves’ Disease - NIDDKniddk.nih.gov
31. Thyroglobulin (Tg) Assaysthyroid.org
32. Haemodynamics of hyperthyroidism: increased cardiac work and findings related to vasodilatationpmc.ncbi.nlm.nih.gov
33. Hyperthyroidism and risk of atrial fibrillation or flutter: a population-based studypubmed.ncbi.nlm.nih.gov
34. Thyrotoxic Atrial Fibrillation: Factors Associated with Persistence and Risk of Ischemic Strokepmc.ncbi.nlm.nih.gov
35. Bone changes in hyperthyroidism: interrelationships between bone morphometry, thyroid function and calcium-phosphorus metabolismpubmed.ncbi.nlm.nih.gov
36. Can bone loss be reversed by antithyroid drug therapy in premenopausal women with Graves' disease?pubmed.ncbi.nlm.nih.gov
37. Hyperthyroid myopathy and the response to treatmentpubmed.ncbi.nlm.nih.gov
38. Skeletal muscle function and body composition of patients with hyperthyroidismpubmed.ncbi.nlm.nih.gov
39. Diagnostic Criteria, Clinical Features, and Incidence of Thyroid Storm Based on Nationwide Surveyspmc.ncbi.nlm.nih.gov
40. Iodine-131 | Radiation Emergencies | CDCcdc.gov
41. Hyperthyroidism in Pregnancythyroid.org
42. Thyroid Disease & Pregnancyniddk.nih.gov
43. 2022 European Thyroid Association Guideline for the management of pediatric Graves’ diseasepmc.ncbi.nlm.nih.gov
44. Guidelines for the treatment of childhood-onset Graves’ disease in Japan, 2016pmc.ncbi.nlm.nih.gov
45. Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in childrenpubmed.ncbi.nlm.nih.gov
46. PROPYLTHIOURACIL TABLETS, USPdailymed.nlm.nih.gov
47. Graves' disease: a long-term quality-of-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery.pubmed.ncbi.nlm.nih.gov